Drug Trial Radar · NCT06041035
A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
115
Planned (sponsor's estimate)
Start
Oct 2023
Primary completion
Oct 2024
Study completion Oct 2025
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of QLS31905 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.
Conditions
- Solid Tumor
Interventions
QLS31905Drug
Administered as an intravenous infusion.
Nab paclitaxelDrug
125 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
GemcitabineDrug
1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.
OxaliplatinDrug
85 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
CapecitabineDrug
1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.
CisplatinDrug
25 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) (Part A)Time frame: Approximately 12 months
- Phase 2 Recommended Dose(RP2D)(Part A)Time frame: Approximately 12 months
- Objective response rate (ORR)(Part B)Time frame: Approximately 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.